CRS-207 + CRS-207 + nivolumab + GVAX + CY
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Previously Treated Metastatic Adenocarcinoma of the Pancreas
Conditions
Previously Treated Metastatic Adenocarcinoma of the Pancreas
Trial Timeline
Jan 2, 2015 → Jul 21, 2017
NCT ID
NCT02243371About CRS-207 + CRS-207 + nivolumab + GVAX + CY
CRS-207 + CRS-207 + nivolumab + GVAX + CY is a phase 2 stage product being developed by Bristol Myers Squibb for Previously Treated Metastatic Adenocarcinoma of the Pancreas. The current trial status is completed. This product is registered under clinical trial identifier NCT02243371. Target conditions include Previously Treated Metastatic Adenocarcinoma of the Pancreas.
What happened to similar drugs?
1 of 3 similar drugs in Previously Treated Metastatic Adenocarcinoma of the Pancreas were approved
Approved (1) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02243371 | Phase 2 | Completed |
Competing Products
8 competing products in Previously Treated Metastatic Adenocarcinoma of the Pancreas
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811 | Jiangsu Hengrui Medicine | Phase 3 | 44 |
| AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim | AstraZeneca | Phase 2 | 27 |
| AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin | AstraZeneca | Phase 2 | 27 |
| UFOX + Cetuximab + FOLFOX4 + Cetuximab | Merck | Phase 2 | 35 |
| Idelalisib + Nab-paclitaxel + mFOLFOX6 | Gilead Sciences | Phase 1 | 21 |
| Bosutinib | Pfizer | Approved | 35 |
| Lenalidomide + Dexamethasone + Elotuzumab | Bristol Myers Squibb | Phase 3 | 32 |
| Oxaliplatin | Sanofi | Phase 2 | 31 |